| Popis: |
Studies of myeloid leukemic cell lines and primary cultures of leukemic bone marrow have yielded information on humoral regulation of growth and differentiation of myeloid cells and have revealed specific abnormalities in regulatory control that would appear to play important roles in the development and progression of hematopoietic neoplasia. Already considerable in vitro data have been accumulated to document the feasibility of the clinical application of such biological response modifiers as Retinoic acid, interferon, tumor necrosis factor, prostaglandin E, and differentiation-inducing proteins in a strategy designed to revert malignant hematopoietic cells to a pattern of normal proliferation and differentiation, or to mediate their selective ablation. Evidence that an effective cancer therapy can be based on induction of a phenotypic reversion of the tumor cell as well as by direct killing of tumor cells has been based on extensive studies on leukemic cell lines such as Friend mouse erythroleukemic cells (39), mouse myeloid (Ml) and myelomonocytic (WEHI- 3) cell lines (33, 71), and human HL-60 myeloid leukemic cells (40). These cell lines can be induced to differentiate and lose self-renewal and leukemogenic capacity following exposure to a variety of chemical agents, including some anticancer drugs (52, 109). |
